Umbilical Cord Blood–Derived Exosomes as Novel Nanocarriers for Targeted Gene Therapy in Insulin Regulation in Diabetes

Umbilical Cord Blood–Derived Exosomes as Novel Nanocarriers for Targeted Gene Therapy in Insulin Regulation in Diabetes

Mahdieh Alsadat Alboshokeh1

1) Department of Biochemistry, Faculty of Basic Sciences, Islamic Azad University, Shahrood Branch, Shahrood Iran

IOI Code : ABEB-ABGAGE
Publication : 4th International Conference on Recent Advances in Engineering, Innovation and Technology - Belgium(eitconf.com)
Abstract :
    Diabetes mellitus is a complex metabolic disorder characterized by impaired insulin secretion, insulin resistance, or a combination of both, leading to chronic hyperglycemia and progressive multisystem complications. Despite advances in pharmacological therapies, current treatment strategies remain largely symptomatic and fail to address the underlying genetic, inflammatory, and cellular mechanisms involved in insulin dysregulation. In this context, gene‑based therapeutic approaches have attracted increasing attention; however, their clinical translation is limited by challenges related to delivery efficiency, safety, and tissue specificity. Umbilical cord blood–derived exosomes (UCB‑ExOs) have recently emerged as a promising biological nanocarrier capable of overcoming these limitations. The primary objective of this review was to critically evaluate the potential of UCB‑ExOs as novel nanocarriers for targeted gene therapy in the regulation of insulin and glucose homeostasis in diabetes. A comprehensive narrative synthesis of recent preclinical studies published between 2022 and 2024 was conducted, focusing on exosome biogenesis, molecular cargo composition, gene regulatory mechanisms, and therapeutic outcomes in diabetic models. Emphasis was placed on experimental evidence demonstrating insulin‑related gene modulation, β‑cell protection, immune regulation, and systemic metabolic improvement. The analyzed findings consistently demonstrate that UCB‑ExOs exert multi‑target therapeutic effects by delivering regulatory RNAs and proteins that modulate key pathways involved in insulin secretion, insulin sensitivity, hepatic gluconeogenesis, inflammation, and vascular function. Preclinical models of both type 1 and type 2 diabetes showed improved glycemic control, enhanced insulin responsiveness, preservation of pancreatic β‑cell integrity, and reduced inflammatory stress following UCB‑ExO administration. Importantly, these effects were achieved with low immunogenicity and favorable biocompatibility, highlighting the safety profile of UCB‑ExOs compared with conventional viral gene delivery systems. In conclusion, UCB‑ExOs represent a versatile and biologically potent platform for targeted gene therapy aimed at restoring physiological insulin regulation. Their capacity to integrate metabolic, immune, and regenerative mechanisms within a single therapeutic modality positions them as a promising candidate for next‑generation, disease‑modifying diabetes treatments, warranting further translational and clinical investigation.

Keywords : umbilical cord blood exosomes targeted gene therapy insulin regulation nanocarriers diabetes mellitus